Advanced Micro Devices Inc/ US0079031078 /
2024-04-26 7:15:17 PM | Chg. +4.1500 | Volume | Bid7:15:17 PM | Ask7:15:17 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
157.9100USD | +2.70% | 27.82 mill. Turnover: 3.61 bill. |
157.9000Bid Size: 300 | 157.9100Ask Size: 200 | 255.41 bill.USD | - | 298.25 |
GlobeNewswire
04-25
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientif...
GlobeNewswire
04-18
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
GlobeNewswire
04-16
AMD Expands Commercial AI PC Portfolio to Deliver Leadership Performance Across Professional Mobile ...
GlobeNewswire
04-16
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...
GlobeNewswire
04-16
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
GlobeNewswire
04-15
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...
GlobeNewswire
04-09
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice Pre...
GlobeNewswire
04-09
AMD Extends Leadership Adaptive SoC Portfolio with New Versal Series Gen 2 Devices Delivering End-to...
GlobeNewswire
04-06
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...